Enumeral Biomedical Holdings, Inc.

Common Stock SEC Reporting - Current
Verified Company Profile 2/16/2017
Contact Info
  • 200 CambridgePark Drive
  • Suite 2000
  • Cambridge, MA 02140

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Mar 31, 2017 10-Q
CIK 0001561551
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Wael Fayad President, CEO
Kevin G Sarney VP, Fin.
Company Directors
Wael Fayad Chairman
Barry Buckland
Robert J. Easton
Robert Van Nostrand
Allan Rothstein
Paul Sekhri
Service Providers
Accounting/Auditing Firm
Friedman LLP
301 Lippincott Drive
4th Floor
Marlton, NJ, 08053
United States
Securities Counsel
Duane Morris LLP
1540 Broadway
New York, NY, 10036-4086
United States
Kevin A. Polis, Esq.
1540 Sixth Ave
San Diego, CA,
United States
Investor Relations Firm

Not Available
Company History
  • Note = Incorporated in Nevada until 7-2014
  • Formerly=Cerulean Group, Inc. until 7-2014
ENUM Security Details
Share Structure
Market Value1 $8,346,636 a/o Jun 21, 2017
Authorized Shares 300,000,000 a/o Sep 30, 2016
Outstanding Shares 128,409,788 a/o Mar 24, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 5,880,314 a/o Feb 24, 2015
Par Value 0.001
Shareholders of Record 407 a/o Mar 28, 2017
Short Selling Data
Short Interest 1,674 (100%)
May 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security